Leuprorelin implant - ALZA

Drug Profile

Leuprorelin implant - ALZA

Alternative Names: Leuprolide acetate implant; Leuprolide implant; Leuprorelin acetate implant; Leuprorelin implant; Viadur; Viadur™

Latest Information Update: 27 Dec 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALZA Corporation; Crescendo Pharmaceuticals
  • Developer ALZA Corporation; Bayer; Crescendo Pharmaceuticals
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 23 Oct 2001 A phase III study has been added to the Cancer therapeutic trials section
  • 28 Jun 2001 ALZA Corporation has been acquired by Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top